Guidelines for Parkinson's disease treatment consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology- motor symptoms
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC ARQUIVOS NEURO- PSIQUIATRIA
Autores
SABA, Roberta Arb
MAIA, Debora Palma
CARDOSO, Francisco Eduardo Costa
BORGES, Vanderci
ANDRADE, Luiz Augusto F.
FERRAZ, Henrique Ballalai
RIEDER, Carlos Roberto de Mello
SILVA, Delson Jose da
Citação
ARQUIVOS DE NEURO-PSIQUIATRIA, v.80, n.3, p.316-329, 2022
Resumo
The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best evidence to the Brazilian reality. Thus, the main published treatment guidelines were reviewed based on the recommendations of group from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology.
O tratamento da doença de Parkinson (DP) constitui um desafio, especialmente por ser considerado muito individualizado. A Academia Brasileira de Neurologia (ABN) identificou a necessidade de disseminar o conhecimento sobre o manejo do tratamento da DP, adaptando as melhores evidências à realidade brasileira. Assim, foi realizada uma revisão sobre as principais orientações de tratamento publicadas, baseada nas recomendações elaboradas por um grupo de especialistas em transtornos do movimento do departamento científico da ABN.
O tratamento da doença de Parkinson (DP) constitui um desafio, especialmente por ser considerado muito individualizado. A Academia Brasileira de Neurologia (ABN) identificou a necessidade de disseminar o conhecimento sobre o manejo do tratamento da DP, adaptando as melhores evidências à realidade brasileira. Assim, foi realizada uma revisão sobre as principais orientações de tratamento publicadas, baseada nas recomendações elaboradas por um grupo de especialistas em transtornos do movimento do departamento científico da ABN.
Palavras-chave
Parkinson Disease, Antiparkinson Agents, Deep Brain Stimulation, Rehabilitation, Doença de Parkinson, Antiparkinsonianos, Estimulação Encefálica Profunda, Reabilitação
Referências
- Andersohn F, 2009, MOVEMENT DISORD, V24, P129, DOI 10.1002/mds.22385
- [Anonymous], 1997, JAMA, V278, P125
- [Anonymous], 2002, Mov Disord, V17 Suppl 4, pS7
- Atkinson-Clement C, 2015, NEURODEGENER DIS MAN, V5, P233, DOI [10.2217/nmt.15.16, 10.2217/NMT.15.16]
- Barichella M, 2006, MOVEMENT DISORD, V21, P1682, DOI 10.1002/mds.21003
- Biglan KM, 2009, ARCH NEUROL-CHICAGO, V66, P563, DOI 10.1001/archneur.66.1.nct90001
- Borgohain R, 2014, MOVEMENT DISORD, V29, P229, DOI 10.1002/mds.25751
- Cabreira V, 2019, DRUGS, V79, P593, DOI 10.1007/s40265-019-01098-w
- Canning CG, 2015, NEUROLOGY, V84, P304, DOI 10.1212/WNL.0000000000001155
- Capato TTC, 2020, PHYS THER, V100, P2023, DOI 10.1093/ptj/pzaa146
- Capato TTC, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117086
- Ory-Magne F, 2014, NEUROLOGY, V82, P300, DOI 10.1212/WNL.0000000000000050
- Pahwa R, 2006, NEUROLOGY, V66, P983, DOI 10.1212/01.wnl.0000215250.82576.87
- PAHWA R, 1993, NEUROLOGY, V43, P677, DOI 10.1212/WNL.43.4.677
- Parkinson J, 2002, J NEUROPSYCH CLIN N, V14, P223, DOI 10.1176/appi.neuropsych.14.2.223
- Parkinson Study Group, 2000, JAMA, V284, P1931
- Perry EK, 2003, ANN NEUROL, V54, P235, DOI 10.1002/ana.10639
- Poewe WH, 2007, LANCET NEUROL, V6, P513, DOI 10.1016/S1474-4422(07)70108-4
- Pollak Pierre, 2013, Handb Clin Neurol, V116, P97, DOI 10.1016/B978-0-444-53497-2.00009-7
- Rao AK, 2010, MOVEMENT DISORD, V25, pS146, DOI 10.1002/mds.22784
- Rascol O, 2005, LANCET, V365, P947, DOI 10.1016/S0140-6736(05)71083-7
- Rochester L, 2010, BRAIN RES, V1319, P103, DOI 10.1016/j.brainres.2010.01.001
- Rodrigues FB, 2017, EXPERT OPIN PHARMACO, V18, P445, DOI 10.1080/14656566.2017.1294683
- Rossi M, 2018, MOV DISORD CLIN PRAC, V5, P246, DOI 10.1002/mdc3.12592
- Rughani A, 2018, NEUROSURGERY, V82, P753, DOI 10.1093/neuros/nyy037
- Schapira AHV, 2013, EUR J NEUROL, V20, P271, DOI 10.1111/j.1468-1331.2012.03840.x
- Schenkman M, 2018, JAMA NEUROL, V75, P219, DOI 10.1001/jamaneurol.2017.3517
- Schwid SR, 2005, ARCH NEUROL-CHICAGO, V62, P241
- Serratrice Jacques, 2002, Cardiol Rev, V10, P334, DOI 10.1097/00045415-200211000-00005
- Shannon KM, 1997, NEUROLOGY, V49, P724, DOI 10.1212/WNL.49.3.724
- SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305
- Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937
- Stocchi F, 2008, MOVEMENT DISORD, V23, pS599, DOI 10.1002/mds.22052
- Stocchi F, 2012, MOVEMENT DISORD, V27, P106, DOI 10.1002/mds.23954
- Strouwen C, 2017, MOVEMENT DISORD, V32, P1201, DOI 10.1002/mds.27014
- Sturkenboom IHWM, 2014, LANCET NEUROL, V13, P557, DOI 10.1016/S1474-4422(14)70055-9
- Thomas A, 2004, J NEUROL NEUROSUR PS, V75, P141
- Tofani M, 2020, MOV DISORD CLIN PRAC, V7, P891, DOI 10.1002/mdc3.13089
- van der Kolk NM, 2019, LANCET NEUROL, V18, P998, DOI 10.1016/S1474-4422(19)30285-6
- Verschuur CVM, 2019, NEW ENGL J MED, V380, P315, DOI 10.1056/NEJMoa1809983
- WALKER JE, 1972, CLIN PHARMACOL THER, V13, P28
- WALKER JE, 1972, J CHRON DIS, V25, P149, DOI 10.1016/0021-9681(72)90171-3
- Watts RL, 2007, NEUROLOGY, V68, P272, DOI 10.1212/01.wnl.0000252355.79284.22
- Widnell KL, 2005, MOVEMENT DISORD, V20, pS30, DOI 10.1002/mds.20461
- Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4
- Wolf E, 2010, MOVEMENT DISORD, V25, P1357, DOI 10.1002/mds.23034
- Wong KS, 2003, J NEUROL SCI, V216, P81, DOI 10.1016/S0022-510X(03)00217-X
- Capato TTC, 2020, J PARKINSON DIS, V10, P333, DOI 10.3233/JPD-191752
- Castrioto A, 2011, ARCH NEUROL-CHICAGO, V68, P1550, DOI 10.1001/archneurol.2011.182
- Cattaneo C, 2016, J PARKINSON DIS, V6, P165, DOI 10.3233/JPD-150700
- Chang Y, 2017, ANN MED, V49, P421, DOI 10.1080/07853890.2017.1293285
- Connolly BS, 2014, JAMA-J AM MED ASSOC, V311, P1670, DOI 10.1001/jama.2014.3654
- Conradsson D, 2015, NEUROREHAB NEURAL RE, V29, P827, DOI 10.1177/1545968314567150
- Contin M, 1996, CLIN PHARMACOKINET, V30, P463, DOI 10.2165/00003088-199630060-00004
- Contin M, 2010, J NEUROL, V257, pS253, DOI 10.1007/s00415-010-5728-8
- Crosby N, 2003, Cochrane Database Syst Rev, pCD003468
- DeLong MR, 2014, JAMA NEUROL, V71, P1290, DOI 10.1001/jamaneurol.2014.1272
- Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
- Durif F, 2004, NEUROLOGY, V62, P381, DOI 10.1212/01.WNL.0000110317.52453.6C
- Espay AJ, 2018, ANN NEUROL, V84, P797, DOI 10.1002/ana.25364
- Fahn S, 2004, NEW ENGL J MED, V351, P2498
- Ferreira JJ, 2013, EUR J NEUROL, V20, P5, DOI 10.1111/j.1468-1331.2012.03866.x
- Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083
- Fox SH, 2018, MOVEMENT DISORD, V33, P1248, DOI 10.1002/mds.27372
- Fox SH, 2013, DRUGS, V73, P1405, DOI 10.1007/s40265-013-0105-4
- Frazzitta G, 2009, MOVEMENT DISORD, V24, P1139, DOI 10.1002/mds.22491
- Freitas ME, 2017, SEMIN NEUROL, V37, P147, DOI 10.1055/s-0037-1602423
- Ghika J, 1997, CLIN NEUROPHARMACOL, V20, P130, DOI 10.1097/00002826-199704000-00004
- Ginis P, 2018, ANN PHYS REHABIL MED, V61, P407, DOI 10.1016/j.rehab.2017.08.002
- Gomide L, 2008, ARQ NEURO-PSIQUIAT, V66, P611, DOI 10.1590/S0004-282X2008000500001
- Gronseth GS., 2017, CLIN PRACTICE GUIDEL, V2017 ed
- Guttman M, 1997, NEUROLOGY, V49, P1060, DOI 10.1212/WNL.49.4.1060
- Hauser RA, 2014, MOVEMENT DISORD, V29, P1028, DOI 10.1002/mds.25877
- HELY MA, 1994, J NEUROL NEUROSUR PS, V57, P903, DOI 10.1136/jnnp.57.8.903
- HUTTON JT, 1984, CLIN NEUROPHARMACOL, V7, P135, DOI 10.1097/00002826-198406000-00003
- Hutton JT, 2001, MOVEMENT DISORD, V16, P459, DOI 10.1002/mds.1085
- Ives NJ, 2004, BMJ-BRIT MED J, V329, P593, DOI 10.1136/bmj.38184.606169.AE
- JABBARI B, 1989, MOVEMENT DISORD, V4, P202, DOI 10.1002/mds.870040302
- Jankovic J, 2007, CNS DRUGS, V21, P677, DOI 10.2165/00023210-200721080-00005
- Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3
- Katzenschlager R, 2003, COCHRANE DB SYST REV, V2002, DOI [10.1002/14651858.CD003735, DOI 10.1002/14651858.CD003735]
- Keus SHJ, 2007, MOVEMENT DISORD, V22, P451, DOI 10.1002/mds.21244
- Koeglsperger T, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00410
- Koller WC, 1999, NEUROLOGY, V53, P1012, DOI 10.1212/WNL.53.5.1012
- Korczyn AD, 1998, MOVEMENT DISORD, V13, P46, DOI 10.1002/mds.870130112
- Krack P, 2019, MOVEMENT DISORD, V34, P1795, DOI 10.1002/mds.27860
- Lee DJ, 2019, J NEUROSURG, V131, P333, DOI 10.3171/2019.4.JNS181761
- LeWitt PA, 2007, NEUROLOGY, V68, P1262, DOI 10.1212/01.wnl.0000259516.61938.bb
- LeWitt PA, 2013, J NEURAL TRANSM, V120, P1069, DOI 10.1007/s00702-012-0925-5
- Lhommee E, 2018, LANCET NEUROL, V17, P223, DOI 10.1016/S1474-4422(18)30035-8
- Li J, 2017, EUR NEUROL, V78, P143, DOI 10.1159/000479555
- Lieberman A, 1997, NEUROLOGY, V49, P162, DOI 10.1212/WNL.49.1.162
- Lim I, 2005, CLIN REHABIL, V19, P695, DOI 10.1191/0269215505cr906oa
- Macleod AD, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004898.pub2, 10.1002/14651858.CD003234.pub2]
- Mak MKY, 2008, MOVEMENT DISORD, V23, P501, DOI 10.1002/mds.21509
- Manor Y, 2013, PARKINSONISM RELAT D, V19, P207, DOI 10.1016/j.parkreldis.2012.10.004
- Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323
- Mizuno Y, 2003, MOVEMENT DISORD, V18, P1149, DOI 10.1002/mds.10508
- Monticone M, 2015, MOVEMENT DISORD, V30, P1050, DOI 10.1002/mds.26256
- Munhoz RP, 2016, CAN J NEUROL SCI, V43, P462, DOI 10.1017/cjn.2016.35
- Nieuwboer A, 2007, J NEUROL NEUROSUR PS, V78, P134, DOI 10.1136/jnnp.200X.097923
- Nutt JG, 2011, LANCET NEUROL, V10, P734, DOI 10.1016/S1474-4422(11)70143-0
- Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335
- Ortelli P, 2018, J PARKINSON DIS, V8, P113, DOI 10.3233/JPD-171247